Home » Ipilimumab / nivolumab significantly improves 12-month nccRCC survival in SUNNIFORECAST

Ipilimumab / nivolumab significantly improves 12-month nccRCC survival in SUNNIFORECAST

by Kevin Kunzmann | Sep 14, 2024 | Articles | 0 Comments